A Phase 3 interventional study of 75 mg linzagolix tablet and 200 mg linzagolix tablet in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 47 sites in 9 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.
Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2020, is one of 5 in phase 3, and was the 8th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2020.
This study's enrollment of 356 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 100 across the 9 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 9 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing linzagolix in Endometriosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07015268Phase 3Kissei Pharmaceutical Co., Ltd.A Clinical Study of KLH-2109 in Patients With Endometriosis | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing linzagolix in Endometriosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have already completed 6 months of linzagolix treatment at a dose of 75 mg alone or of 200 mg in combination with ABT (E2 1 mg / NETA 0.5 mg), in the management of moderate to severe endometriosis-associated pain (EAP) in women with surgically confirmed endometriosis.
This is a prospective, randomized, double-blind study. Subjects who have completed the 6-month Treatment Period in 18-OBE2109-003 - Edelweiss 3 study (herein referred to as main study) will be invited to enter the present extension study. Month 6 visit of the main study is a decision point for Subjects to either end treatment and enter a post-treatment follow up (part of the main study), or to opt for a 6-month treatment extension.
All subjects will receive once daily either linzagolix 75 mg alone (with ABT placebo) or 200 mg combined with ABT for 6 months. Subjects who received placebo during the main study will be randomized to either linzagolix 75 mg alone (with ABT placebo) or linzagolix 200 mg with ABT. Subjects who received active treatment during the main study will continue with the same treatment. Double-dummy design will be used in order to maintain the blinding of the study.
After end of treatment in the extension study (6-month treatment period: from Month 6 to Month 12), subjects will enter a post-treatment Follow-Up Period of 6 months with no investigational medicinal product (IMP) or - for subjects willing to continue treatment - a second extension study will be proposed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject must have:
Exclusion Criteria:
The subject will be excluded if she:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 75 mg linzagolix tablet · Drug: Placebo tablet to match 200 mg linzagolix tablet · Drug: Placebo capsule to match Add-back capsule
Drug: 200 mg linzagolix tablet · Drug: Placebo tablet to match 75 mg linzagolix tablet · Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)
For oral administration once daily
For oral administration once daily
For oral administration once daily
For oral administration once daily
Drug page: Estradiol
For oral administration once daily
For oral administration once daily
Dysmenorrhea
Proportion of subjects with reduction of DYS (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12
Time frame: 6-month extension study treatment period (from Month 6 to Month 12)
Non-menstrual Pelvic Pain
Proportion of subjects with reduction of NMPP (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12
Time frame: 6-month extension study treatment period (from Month 6 to Month 12)
Overall, 356 subjects entered the extension study and were treated. With the exception of 3 subjects who met a discontinuation criterion at Month 6, all other subjects who entered the extension study were included in the TEAS. The PP EAS consisted of 336 subjects. All 356 subjects who entered the extension study were included in the ESAF.
| Milestone | LGX 75 mg | LGX 200 mg+ABT | Placebo / LGX 75 mg | Placebo / LGX 200 mg+ABT |
|---|---|---|---|---|
| Started | 119 | 122 | 58 | 57 |
| Completed | 101 | 110 | 49 | 50 |
| Not completed | 18 | 12 | 9 | 7 |
| Withdrew: Adverse event | 5 | 2 | 3 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 4 | 4 | 5 |
| Withdrew: Subject planning pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Ukrainian russian war conflict | 4 | 5 | 2 | 0 |
Proportion of subjects with reduction of DYS (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12
| Participants | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT |
|---|---|---|---|---|
| Dysmenorrhea | 62 | 101 | 32 | 43 |
Proportion of subjects with reduction of NMPP (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12
| Participants | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT |
|---|---|---|---|---|
| Non-menstrual Pelvic Pain | 66 | 75 | 34 | 27 |
Collected over 6-month extension study treatment period (from Month 6 to Month 12). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LGX 75 mg | 0/119 (0%) | 3/119 (2.5%) | 26/119 (21.8%) |
| LGX 200 mg+ABT | 0/122 (0%) | 0/122 (0%) | 19/122 (15.6%) |
| Placebo/LGX 75 mg | 0/58 (0%) | 0/58 (0%) | 15/58 (25.9%) |
| Placebo/LGX 200 mg+ABT | 0/57 (0%) | 1/57 (1.8%) | 13/57 (22.8%) |
| Event | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT |
|---|---|---|---|---|
| Genital haemorrhageReproductive system and breast disorders | 0/119 | 0/122 | 0/58 | 1/57 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/119 | 0/122 | 0/58 | 0/57 |
| CholelithiasisHepatobiliary disorders | 1/119 | 0/122 | 0/58 | 0/57 |
| AnxietyPsychiatric disorders | 1/119 | 0/122 | 0/58 | 0/57 |
| Event | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT |
|---|---|---|---|---|
| Hot flushVascular disorders | 4/119 | 5/122 | 4/58 | 0/57 |
| AnaemiaBlood and lymphatic system disorders | 7/119 | 0/122 | 3/58 | 2/57 |
| HeadacheNervous system disorders | 5/119 | 3/122 | 3/58 | 3/57 |
| Vaginal haemorrhageReproductive system and breast disorders | 3/119 | 3/122 | 1/58 | 3/57 |
| Vulvovaginal mycotic infectionInfections and infestations | 1/119 | 2/122 | 3/58 | 3/57 |
| COVID-19Infections and infestations | 6/119 | 6/122 | 1/58 | 2/57 |
| Age, Categorical(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 119 | 122 | 58 | 57 | 356 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(Years) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| Mean | 35.1 ± 6.3 | 34.8 ± 6.9 | 34.3 ± 6.6 | 35.0 ± 7.7 | 34.8 ± 6.8 |
| Age, Customized(Years) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| Median | 35.0 (31.0 to 40.0) | 35.0 (29.0 to 40.0) | 34.5 (30.0 to 40.0) | 36.0 (30.0 to 41.0) | 35.0 (30.0 to 40.0) |
| Sex: Female, Male(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| Female | 119 | 122 | 58 | 57 | 356 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 1 | 0 | 8 |
| Not Hispanic or Latino | 117 | 117 | 57 | 57 | 348 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 1 | 3 |
| White | 117 | 120 | 58 | 56 | 351 |
| More than one race | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| Austria | 0 | 0 | 1 | 0 | 1 |
| Romania | 6 | 7 | 4 | 3 | 20 |
| Czechia | 1 | 3 | 0 | 0 | 4 |
| Ukraine | 59 | 50 | 30 | 24 | 163 |
| Poland | 46 | 51 | 21 | 27 | 145 |
| Bulgaria | 2 | 3 | 0 | 1 | 6 |
| Spain | 1 | 0 | 0 | 0 | 1 |
| United States | 4 | 8 | 2 | 2 | 16 |
| Weight(kg) | LGX 75 mg | LGX 200 mg+ABT | Placebo/LGX 75 mg | Placebo/LGX 200 mg+ABT | Total |
|---|---|---|---|---|---|
| Mean | 68.475 ± 15.115 | 65.210 ± 13.497 | 64.004 ± 11.103 | 68.029 ± 13.826 | 66.560 ± 13.830 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2020 to primary completion in Sep 2022, 30 months.
Results were first posted in Apr 2024, 1 year 7 months after primary completion.
Of 33 phase 3 interventional studies under Endometriosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linzagolix
Kissei Pharmaceutical Co., Ltd. →